

Programa Best of Astro 2024



04

abril 2025

Salón Quixote

Centro de Convenciones
Hotel Sheraton - Santiago.
Av. Santa María 1742, Providencia



VIERNES, 4 DE ABRIL DE 2025

07:30 – 08:00 Inscripciones y registro

08:00 – 08:15
Palabras de bienvenida

08:15 – 09:00 Módulo genitourinario Moderador: Dr.Tomas Merino
Expositor: Dr. Piero Bettolli

Abstracts

- Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
- Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
- Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
- Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher - Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials
- A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High Risk Prostate Cancer: Efficacy Results at Median 6 Years Follow Up
- Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial
- Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses
- Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer
- Outcomes of Radium-223 and SABR vs. SABR for oligometastatic prostate cancer – The RAVENS Phase II Randomized Trial
- Bladder Adjuvant Radiotherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial
- Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial



9:00 – 10:00 Módulo gastrointestinal

Moderador: Dr. Jorge Gallardo
Expositor: Dr. Pablo Muñoz

Abstracts


- Long-Term Prognostic Analysis of Chemoradiotherapy vs. Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results from a Prospective Randomized Control Study
- Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the OPRA Trial
- Personalized Minimal Residual Disease Profiling Predicts Prognosis in Esophageal Carcinoma Undergoing Definitive Radiotherapy
- Multi-Institutional Comparison of Ablative 5-Fraction MR-Guided Online Adapted vs. 15/25-Fraction CT-Guided Offline Adapted Radiation Therapy for Locally Advanced Pancreas Cancer
- Neoadjuvant Toripalimab plus Concurrent Chemoradiotherapy in the Locally Advanced Adenocarcinoma of Esophagogastric Junction: A Phase II Trial Radiation Quality Control in the PROSPECT Trial
- Outcomes and Immune Responses from INNATE: A Randomized Phase II Trial of Sotigalimab Immunotherapy during Neoadjuvant Therapy of Rectal Cancer
- A Multicenter Phase III Randomized Clinical Trial Comparing the Efficacy of an Adjuvant SOX Chemotherapy Regimen with SOX Combined with a Simultaneous Radiotherapy Regimen after D2 Radical Resection for Gastric Cancer
- Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC – A Randomized Controlled Prospective Multicenter Phase III Trial

Mesa Redonda

Integrantes: Dr. Pablo Muñoz, Dr. Jorge Gallardo, Dr. Sebastián Solé,
Dr. Hyun Kim  , Dr. Benjamín Calvo 

10:00 – 10:30

Coffee break

10:30 – 11:00	Conferencia Magistral <i>Moving RPT into the Mainstream of RO and Navigating the Collaboration with NM</i>	Moderadora: Dra. Isidora King Expositor: Dr. Hyun Kim 
---------------	--	--

11:00 - 11:30	Módulo cuidados paliativos y partes blandas	Moderadora: Dra. Evelyn San Martín Expositora: Dra. Lorena Vargas
---------------	---	--

Abstracts

- A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes
- Reduction of Bone Fracture after Radiotherapy in Lower Extremity Soft Tissue Sarcoma after Implementing Bone Avoidance Objectives for Radiotherapy Planning
- Efficacy of Kangfuxin Liquid Retention Enema in Preventing and Treating Radiation-Induced Proctitis in Cervical Cancer Patients: A Randomized, Open-Label, Phase III Study
- Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial
- Phase 2 Trial of Stereotactic MR-Guided Adaptive Radiation Therapy in One Fraction (SMART ONE)
- ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer

Abstracts

- Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma – Long-Term Results of Expanded Cohort
- A Phase II Trial of Camrelizumab in Combination with Concurrent Chemoradiotherapy as First-Line Treatment for Betel Nut-Related Locally Advanced Oral Squamous Cell Carcinoma
- Acupuncture for (Chemo)Radiotherapy – Related Dysphagia in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase 2 Study
- HYHOPE: A Phase I Study of De-Intensified Hypofractionated Radiation Therapy for Human Papillomavirus-Associated Oropharynx Cancer
- Quality of Life (QOL) of Patients with Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
- HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
- Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients
- A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma
- Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Multicenter, Randomized Phase III Trial

12:15 - 13:00

Módulo cáncer pulmonar

Moderador: Dr. Claudio Solé P.
Expositor: Dr. Alejandro Santini

Abstracts

- Pirfenidone in the Treatment of Radiation-Induced Lung Injury: A Randomized, Controlled, Multicenter Clinical Trial
- Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial
- Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
- Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)
- Long-Term Outcomes of Postoperative Radiotherapy for Patients with pIIIA-N2 Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
- Measuring the Integration of Stereotactic Ablative Radiotherapy plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes
- Simultaneous Integrated Boost vs. Conventional Radiotherapy for Patients with Limited-Stage Small Cell Lung Cancer: A Randomized, Non-Inferiority, Open- Label, Phase 3 Trial
- The Impact of Prophylactic Bisphosphonates on Radiation-Induced Rib Fractures and Chest Wall Pain in Peripheral Lung Tumor SBRT: A Randomized, Double-Blind, Placebo-Controlled Study
- Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: Final Results from a Nonrandomized Controlled Clinical Trial
- Concurrent Chemoradiation +/- Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005
- Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)


13:00 - 13:45

Simposio AstraZeneca

Nuevo estándar en el Tratamiento del Cáncer de Pulmón irresecable con Mutación EGFR: Resultados del Estudio LAURA

Moderador: Dr. Ilan Perrot
Expositor: Dr. Claudio Solé

13:45 - 14:45 Simposio Varian y Almuerzo
Clinical benefits of Halcyon with
HyperSight

Moderador: Dr. Ilan Perrot
Expositor: Dr. Hyun Kim 

14:45 – 15:30 Módulo sistema nervioso central

Moderador: Dr. Eugenio Vinés
Expositora: Dra. Loreto Yáñez

Abstracts

- A Prospective, Phase II Study of ¹⁷⁷Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort
- Proton Craniospinal Irradiation for Patients with Solid Tumor Leptomeningeal Metastasis- Final Analysis of a Phase II Study
- Phase I/II Prospective Dose Escalation Trial with Proton-Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncology Group 85-26
- Risk of Radiation Myelitis after Hypofractionated Spine Stereotactic Body Radiation Therapy
- Target Volume Delineation for the Re-Irradiation of Recurrent Glioblastoma: MRI or PET-Based? Results of the GLIAA Prospective Randomized Trial
- Evaluating Neurocognitive Recovery Following Stereotactic Radiosurgery and Whole Brain Radiation Therapy: Insights from a Pooled Analysis of Three Phase III Trials
- MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial
- Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial

Abstracts

- A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings
- Induction Chemotherapy plus Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone in High-Risk Locally Advanced Cervical Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
- Induction Chemotherapy plus Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone in High-Risk Locally Advanced Cervical Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
- IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
- Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial
- Phase I Clinical Trial of Lobaplatin Combined with Image-Guided Volume-Modulated Arc Radiation Therapy in Locally Advanced Cervical Cancer
- Five-Year Outcomes of a Phase II Study of Post-Operative Proton Beam Radiation for Gynecologic Cancers
- Comparison of Docetaxel and Cisplatin Concurrent and Short-Course Adjuvant Chemotherapy with Cisplatin Concurrent Chemotherapy in Radiotherapy for Locally Advanced Cervical Cancer: A Phase III Multicenter Randomized Trial

Abstracts

- Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma
- Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia
- Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Children's Oncology Group AHOD 0431
- Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma prior to CAR T-Cell Therapy
- Initial Results of the Multicenter Phase II Trial of a Novel Hypofractionated Low-Dose Radiotherapy for Indolent Non-Hodgkin Lymphoma
- Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma – First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG)
- A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort

17:30 – 18:15

Módulo cáncer de mama

Moderador: Dra. Karen Goset
Expositora: Dra. Valentina Ovalle

Abstracts

- A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
- Hypofractionated Whole-Breast Irradiation with Simultaneous Integrated Boost for Breast Cancer: Primary Analysis of the HYPOSIB-Trial (ARO 2013-05)
- Primary Outcome Analysis for Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized, Phase III Trial of Hypo- vs. Conventionally Fractionated Regional Nodal Irradiation (RNI)
- Five vs. Three Fractions of Prone Accelerated Partial Breast Irradiation: Results of a Randomized Controlled Phase 3 Non-Inferiority Trial
- The Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events Following Modern Breast Radiotherapy
- A Virtual Program for Fatigue among Women Undergoing Radiation Treatment: Results from a Randomized Controlled Basket Trial
- Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer: The TENDANCE Multicentric French Study (Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer)
- Characterization of Skin Microbiome Profile before and during Radiation Therapy and Its Correlation to the Occurrence and Severity of Radiation Dermatitis

18:15

Palabras de Cierre
